RGD motif enhances immunogenicity and adjuvanicity of peptide antigens following intranasal immunization

Vaccine

Volumn 22, Issue 2, 2003, Pages 237-243

  Yano, Akira ^a   Onozuka, Atsuko ^a   Matin, Khairul ^a,b   Imai, Susumu ^a   Hanada, Nobuhiro ^a   Nisizawa, Tosiki ^a,c  

^a NATIONAL INSTITUTE OF PUBLIC HEALTH   (Japan)

^b Bangladesh Medical Studies and Research Institute   (Bangladesh)

^c HAYASHIBARA BIOCHEMICAL LABORATORIES INC   (Japan)

Author keywords

Cell attachment motif; Nasal immunization; Peptide adjuvant; Peptide vaccine

Indexed keywords

ANTIBODY; ARGINYLGLUTAMYLASPARTIC ACID; ARGINYLGLYCYLASPARTIC ACID; ARGINYLLYSYLLYSINE; ARGINYLPHENYLALANYLTYROSYLVALYLVALYLMETHIONYLTRYPTOPHYLLYSINE; ASPARTYLGLYCYLGLUTAMYLALANINE; IMMUNOLOGICAL ADJUVANT; ISOLEUCYLARGINYLVALYLVALYLMETHIONINE; ISOLEUCYLLYSYLVALYLALANYLVALINE; LEUCYLASPARTYLVALINE; PEPTIDE ADJUVANT; PEPTIDE DERIVATIVE; PEPTIDE VACCINE; PROLYLHISTIDYLSERYLARGINYLASPARAGINE; TYROSYLISOLEUCYLGLYCYLSERYLARGININE; UNCLASSIFIED DRUG;

AMINO ACID SEQUENCE; ANIMAL EXPERIMENT; ANTIBODY BLOOD LEVEL; ANTIBODY TITER; ARTICLE; CELL ADHESION; CONTROLLED STUDY; DRUG EFFECT; DRUG SYNTHESIS; IMMUNIZATION; IMMUNOGENICITY; INFECTION; MOLECULAR BIOLOGY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN MOTIF; PROTEIN PROTEIN INTERACTION;

EID: 0242575937     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0264-410X(03)00561-9     Document Type: Article

References (34)

1. BenMohamed L., Wechsler S.L., Nesburn A.B. Lipopeptide vaccines - yesterday, today, and tomorrow. Lancet Infect. Dis. 2(7):2002;425-431.
2. Lennon-Duménil A.M., Bakker A.H., Wolf-Bryant P., Ploegh H.L., Lagaudrière-Gesbert C. A closer look at proteolysis and MHC-class-II-restricted antigen presentation. Curr. Opin. Immunol. 14(1):2002;15-21.
3. Bjorkman P.J. MHC restriction in three dimensions: a view of T cell receptor/ligand interactions. Cell. 89(2):1997;167-170.
4. Wilson C.C., Palmer B., Southwood S., Sidney J., Higashimoto Y., Appella E.et al. Identification and antigenicity of broadly cross-reactive and conserved human immunodeficiency virus type 1-derived helper T- lymphocyte epitopes. J. Virol. 75(9):2001;4195-4207.
5. Partidos C.D., Beignon A.S., Semetey V., Briand J.P., Muller S. The bare skin and the nose as non-invasive routes for administering peptide vaccines. Vaccine. 19(17-19):2001;2708-2715.
6. Bouvet J.P., Decroix N., Pamonsinlapatham P. Stimulation of local antibody production: parenteral or mucosal vaccination? Trends Immunol. 23(4):2002;209-213.
7. Fujihashi K., Koga T., van Ginkel F.W., Hagiwara Y., McGhee J.R. A dilemma for mucosal vaccination: efficacy versus toxicity using enterotoxin-based adjuvants. Vaccine. 20(19-20):2002;2431-2438.
8. Tam J.P. Synthetic peptide vaccine design: synthesis and properties of a high-density multiple antigenic peptide system. Proc. Natl. Acad. Sci. U.S.A. 85(15):1988;5409-5413.
9. Alving C.R., Koulchin V., Glenn G.M., Rao M. Liposomes as carriers of peptide antigens: induction of antibodies and cytotoxic T lymphocytes to conjugated and unconjugated peptides. Immunol. Rev. 145:1995;5-31.
10. Kato H., Takeuchi H., Oishi Y., Senpuku H., Shimura N., Hanada N.et al. The immunogenicity of various peptide antigens inducing cross-reacting antibodies to a cell surface protein antigen of Streptococcus mutans. Oral Microbiol. Immunol. 14(4):1999;213-219.
11. Oishi Y., Onozuka A., Kato H., Shimura N., Imai S., Nisizawa T. The effect of amino acid spacers on the antigenicity of dimeric peptide-inducing cross-reacting antibodies to a cell surface protein antigen of Streptococcus mutans. Oral Microbiol. Immunol. 16(1):2001;40-44.
12. Okahashi N., Sasakawa C., Yoshikawa M., Hamada S., Koga T. Cloning of a surface protein antigen gene from serotype c Streptococcus mutans. Mol. Microbiol. 3(2):1989;221-228.
13. Senpuku H., Miyauchi T., Hanada N., Nisizawa T. An antigenic peptide inducing the cross-inhibiting antibodies against the interaction of Streptococcus mutans PAc with human salivary components. Infect. Immun. 63(12):1995;4695-4703.
14. Ruoslahti E. Fibronectin and its receptors. Annu. Rev. Biochem. 57:1988;375-413.
15. Ruoslahti E. RGD and other recognition sequences for integrins. Annu. Rev. Cell Dev. Biol. 12:1996;697-715.
16. Mecham R.P. Laminin receptors. Annu. Rev. Cell Biol. 7:1991;71-91.
17. Pierschbacher M.D., Ruoslahti E. Cell attachment activity of fibronectin can be duplicated by small synthetic fragments of the molecule. Nature. 309(5963):1984;30-33.
18. Aota S., Nomizu M., Yamada K.M. The short amino acid sequence Pro-His-Ser-Arg-Asn in human fibronectin enhances cell-adhesive function. J. Biol. Chem. 269(40):1994;24756-24761.
19. 2I domain. J. Biol. Chem. 274(6):1999;3513-3521.
20. 1 integrin in collagen. J. Biol. Chem. 266(12):1991;7363-7367.
21. Kosfeld M.D., Frazier W.A. Identification of a new cell adhesion motif in two homologous peptides from the COOH-terminal cell binding domain of human thrombospondin. J. Biol. Chem. 268(12):1993;8808-8814.
22. Rappuoli R., Pizza M., Douce G., Dougan G. Structure and mucosal adjuvanticity of cholera and Escherichia coli heat-labile enterotoxins. Immunol. Today. 20(11):1999;493-500.
23. Blaschuk O.W., Sullivan R., David S., Poulit Y. Identification of a cadherin cell adhesion recognition sequence. Dev. Biol. 139(1):1990;227-229.
24. Takeichi M. Cadherin cell adhesion receptors as a morphogenetic regulator. Science. 251(5000):1991;1451-1455.
25. Ahlers J.D., Takeshita T., Pendleton C.D., Berzofsky J.A. Enhanced immunogenicity of HIV-1 vaccine construct by modification of the native peptide sequence. Proc. Natl. Acad. Sci. U.S.A. 94(20):1997;10856-10861.
26. Korber B, Brander C, Haynes B, Koup R, Kuiken C, Moore JP, et al. HIV helper-T cell epitopes. In: HIV molecular immunology 2001. New Mexico: Los Alamos National Laboratory; 1999. p. III-A62-6.
27. d. Science. 256(5065):1992;1817-1820.
28. Ulmer J.B., Liu M.A. Ethical issues for vaccines and immunization. Nat. Rev. Immunol. 2(4):2002;291-296.
29. Lavelle E.C., Grant G., Pusztai A., Pfüller U., O'Hagan D.T. The identification of plant lectins with mucosal adjuvant activity. Immunology. 102(1):2001;77-86.
30. McCluskie M.J., Weeratna R.D., Krieg A.M., Davis H.L. CpG DNA is an effective oral adjuvant to protein antigens in mice. Vaccine. 19(7-8):2001;950-957.
31. 3 antagonists promote tumor regression by inducing apoptosis of angiogenic blood vessels. Cell. 79(7):1994;1157-1164.
32. 3 integrin inhibits bone resorption in vitro and prevents osteoporosis in vivo. J. Clin. Invest. 99(9):1997;2284-2292.
33. Savi P., Badorc A., Lale A., Bordes M.F., Labouret C., Bernat A.et al. SR 121787, a new orally active fibrinogen receptor antagonist. Thromb. Haemost. 80(3):1998;469-476.
34. 3 inhibits Leydig cell tumor growth and the development of hypercalcemia of malignancy. Cancer Res. 58(9):1998;1930-1935.